한국지질동맥경화학회 학술대회

Insulin resistance is a key pathophysiology underlying metabolic disorders and is closely associated with the development of atherosclerotic cardiovascular disease (ASCVD). The triglyceride-glucose (TyG) index is a novel and simple surrogate marker of insulin resistance, calculated using fasting triglyceride and glucose levels, and has demonstrated comparable accuracy to HOMA-IR. In this session, we will explore the clinical role of the TyG index based on recent national and international studies regarding its predictive value for ASCVD. Professor Patricio Lopez-Jaramillo from Universidad de Santander, Colombia, will present multinational data on the association between the TyG index and ASCVD. Professor Yong-Jae Lee from Yonsei University College of Medicine, Republic of Korea, will share findings from Korean data on the same topic. Finally, Professor Ki-Bum Won from Chung-Ang University College of Medicine, Republic of Korea, will offer a lecture on the relationship between the TyG index and coronary artery calcification.

This session, "Genetic Insights into Dyslipidemia and Diabetes: Pathways, Predictions, and Interventions," delves into the latest genetic advances impacting cardiovascular and metabolic diseases. Attendees will explore the evolving genetic landscape of cardiovascular disease (CVD) and diabetes, considering future implications for prediction and prevention. The second presentation examines the powers of multi-omics and multi-trait analyses in unraveling the complexity of metabolic disorders. Next, exciting developments in gene therapy for familial hypercholesterolemia will be showcased, highlighting cutting-edge interventions. The session concludes with an engaging discussion, fostering collaboration and reflection on how genetic research can translate into better clinical outcomes.

This session entitled “Emerging Drugs for Dyslipidemia Management” addresses innovative pharmacological strategies to tackle residual lipid risk that persists despite statin therapy. While LDL-C reduction remains the cornerstone of dyslipidemia management, a substantial number of patients continue to face elevated cardiovascular risk due to hypertriglyceridemia, elevated remnant cholesterol, or persistent atherogenic dyslipidemia. The first lecture will examine the real-world clinical applications of bempedoic acid and identify patient populations who may derive maximum therapeutic benefit. The second lecture will focus on APOC3 inhibition strategies for severe hypertriglyceridemia management, discussing clinical applicability in familial chylomicronemia syndrome and mixed dyslipidemia with supporting evidence from recent clinical trials. The final lecture will present the regulatory mechanisms of ANGPTL3 and ANGPTL8 in lipid metabolism and introduce the development status of next-generation therapeutic approaches targeting these pathways. Through this session, attendees will gain comprehensive insights into the latest paradigms in lipid-lowering therapy and future prospects for clinical implementation.

“Dyslipidemia Management in Special Populations” explores lipid-lowering strategies tailored to unique clinical contexts. Professor Mina Kim (Korea University, Republic of Korea) will address dyslipidemia management in women before and after menopause, highlighting hormonal influences on cardiovascular risk. Professor Byung Sik Kim (Hanyang University, Republic of Korea) will discuss lipid management in patients with liver disease, focusing on the safe and effective use of statins in this vulnerable group. Finally, Professor Seonghoon Choi (Hallym University, Republic of Korea) will present on dyslipidemia in the setting of HIV infection and chronic inflammation, emphasizing pathophysiological mechanisms and therapeutic challenges. This session will provide practical insights into individualized dyslipidemia care for patients with complex comorbidities and diverse physiological backgrounds.